A randomized phase II study to investigate the deepness of response of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer patients with RAS wild-type tumors: DEEPER
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2017
At a glance
- Drugs Cetuximab (Primary) ; Bevacizumab; Fluorouracil; Irinotecan; Levofolinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms DEEPER
- 21 Jan 2017 According to trial design presented at the 2017 Gastrointestinal Cancers Symposium, thirty-three patients have been enrolled as of August 2016.
- 21 Jan 2017 Trial design presented at the 2017 Gastrointestinal Cancers Symposium
- 15 Nov 2016 Planned End Date changed from 14 Jul 2021 to 30 Jun 2020.